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The intestinal microbiota has been linked to the development and prevalence of steatohepatitis in humans. Interestingly, 
steatohepatitis is significantly lower in individuals taking a plant-based, low-animal-protein diet, which is thought to be 
mediated by gut microbiota. However, data on causality between these observations in humans is scarce. In this regard, 
fecal microbiota transplantation (FMT) using healthy donors is safe and is capable of changing microbial composition 
in human disease. We therefore performed a double-blind randomized controlled proof-of-principle study in which indi-
viduals with hepatic steatosis on ultrasound were randomized to two study arms: lean vegan donor (allogenic n  =  10) or 
own  (autologous n  =  11) FMT. Both were performed three times at 8-week intervals. A liver biopsy was performed at 
baseline and after 24  weeks in every subject to determine histopathology (Nonalcoholic Steatohepatitis Clinical Research 
Network) classification and changes in hepatic gene expression based on RNA sequencing. Secondary outcome parameters 
were changes in intestinal microbiota composition and fasting plasma metabolomics. We observed a trend toward improved 
necro-inflammatory histology, and found significant changes in expression of hepatic genes involved in inflammation and 
lipid metabolism following allogenic FMT. Intestinal microbial community structure changed following allogenic FMT, 
which was associated with changes in plasma metabolites as well as markers of . Conclusion: Allogenic FMT using lean 
vegan donors in individuals with hepatic steatosis shows an effect on intestinal microbiota composition, which is associated 
with beneficial changes in plasma metabolites and markers of steatohepatitis. (Hepatology Communications 2020;4:1578-1590).
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As a consequence of the pandemic spread of obesity and type 2 diabetes (T2DM), nonal-coholic fatty liver disease (NAFLD) is now 
recognized as the most prevalent chronic liver dis-
ease worldwide.(1) NAFLD represents a spectrum of 
liver disease, with clinical and histological abnormal-
ities ranging from simple steatosis (nonalcoholic fatty 
liver) to nonalcoholic steatohepatitis (NASH), with 
the latter being diagnosed when the liver biopsy shows 
hepatocyte ballooning and inflammation, in addition 
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to steatosis. The current estimated global prevalence of 
NAFLD is 25%-30% and reaching staggering numbers 
up to 80% in individuals with metabolic syndrome and 
T2DM.(1) Although it has been showed that individu-
als with NAFLD can progress toward NASH,(2,3) the 
presence of steatosis has little prognostic value for dis-
ease development.(4) Increasing evidence suggests that 
disease activity, also known as the necro-inflammation 
score (i.e., inflammation and hepatocyte ballooning), 
independent of steatosis is clinically the most relevant 
parameter of NAFLD.(5,6) This relatively new concept 
in steatohepatitis describes and measures inflamma-
tion and liver cell injury and builds on the evidence 
that disease activity is highly associated with fibrosis 
progression.(5,6) Similarly, individuals with a high necro- 
inflammation score, thus high active inflammation, 
have a considerably higher risk of developing hepatic 
(cirrhosis, hepatocellular carcinoma, liver transplanta-
tion) and extrahepatic (primarily atherosclerotic car-
diovascular) complications.(1) As annual medical costs 
directly attributable to NAFLD keep increasing per 
year, this underscores the need of interventions to 
alleviate or even prevent an adverse disease course.(1,7)
In search of potential new and effective treatment 
options, the gut microbiome has gained a lot of interest, 
primarily based on human observational studies and 
animal experiments. Indeed, alterations in gut micro-
bial composition have frequently been observed in 
individuals with NAFLD.(8-10) Accordingly, alterations 
in plasma metabolites derived from gut microbiota as 
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What is already known about this subject?
• Gut microbiota are involved in human health and (metabolic) disease;
• Changes in fecal microbiota are associated with hepatic steatosis; and
• Animal studies have suggested that fecal transplantation can alter steatohepatitis.
What are the new findings?
• Fecal microbiota transplantation (FMT) from vegan lean donors improves histological (necro-inflammation score) and liver gene 
expression in liver biopsies of subjects with steatohepatitis;
• These differential changes are accompanied by alterations in plasma metabolites and fecal microbiota composition; and
• New correlations between changes in microbiota strains and plasma metabolites in relation to liver gene expression and histology in 
human steatohepatitis are observed.
How might it affect clinical practice in the foreseeable future?
• This study helps to quantify the magnitude of gut microbiota–driven effects on human steatohepatitis using FMT; and
• This study provides sample sizes for future trials and underscores that dietary intake plays a role in gut microbiota function and 
subsequent development of metabolic complications like steatohepatitis.
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well as from diet have been linked to NAFLD devel-
opment.(9) Compared with omnivorous diets, plant-
based low-animal-protein diets, as practiced by vegans, 
are associated with reduced NAFLD incidence.(11) 
Compared with omnivores, vegans have an altered gut 
microbiota composition(12) with concomitant alterations 
in plasma metabolites such as carnitine derivatives.(13) 
This has previously been linked to a lower incidence 
of NAFLD in Chinese(14) and Western subjects.(11) 
Although causality of these gut microbiota alterations 
on liver disease has been suggested in mice, in humans 
this remains to be elucidated. To find the cause-and-ef-
fect relations between the gut microbiome and human 
disease in general, feces from affected individuals have 
been transplanted into rodents.(15) Interestingly, in 
a recent systematic review, it was shown that 95% of 
published studies described the successful transfer of 
the pathological phenotype of human NAFLD into 
rodents, indicative of substantial publication bias, as 
many studies were underpowered.(16) Combined with 
the complexity of causal relations, these findings sug-
gest that this high success rate of interspecies trans-
ferable pathologies overestimates the role of the gut 
microbiome in human disease.(16) Lessons from studies 
performing fecal microbiota transplantation (FMT) in 
humans have shown that FMT is relatively safe when 
performed in a clinical setting and capable of changing 
gut microbial composition with concomitant (modest) 
effects on human metabolism. For example, transfer of 
healthy donor feces was found to improve insulin sensi-
tivity, alter short chain fatty acid production, and affect 
plasma metabolite levels in individuals with metabolic 
syndrome.(17) Nevertheless, not all FMTs change the 
metabolic traits or microbiota composition in treated 
individuals,(17) and the effect appears to be modulated 
by the donor’s metabolic status as well as the recipient’s 
microbiota composition.(18) This underscores the com-
plexity of the relation among human diet, metabolism, 
composition, and function of the gut microbiome in 
relation to cardiometabolic diseases and NAFLD. It 
also suggests that (diet-specific) personal characteristics 
of both donor and acceptor determine the individual’s 
response following donor FMT.(19) To date, dissecting 
the causality of intestinal microbiota in NAFLD using 
FMT from donors on a plant-based, low-animal-pro-
tein diet has not been performed. Therefore, the aim 
of our pilot randomized controlled trial study was to 
investigate a potential causal role of intestinal microbi-
ota on NAFLD in humans.
Methods
Design
This study was a single-center, double-blind, ran-
domized controlled proof-of-principle pilot study 
comparing the effect of three 8-weekly lean vegan 
donor FMT versus autologous FMT on the severity 
of NAFLD, using liver biopsies in individuals with 
hepatic steatosis on ultrasound (Supporting Fig. S1). 
The study was conducted in the Amsterdam University 
Medical Centers, located at the Academic Medical 
Center (AMC METC 2013_207), in compliance 
with the principles of the declaration of Helsinki and 
CONSORT guidelines. The protocol was reviewed 
and approved by the institutional review board of the 
AMC, and was registered in the Dutch Trial Register 
(registration number NTR4339). All participants pro-
vided written, informed consent.
paRtiCipants anD DonoRs
Caucasian, overweight, treatment-naïve, omnivo-
rous individuals with hepatic steatosis on ultrasound 
were included. The main inclusion criteria were age 
21-69  years, male or postmenopausal female, body 
mass index (BMI)  >  25  kg/m2 with hepatic steato-
sis on previous ultrasound with suspicion of NAFLD 
(based on elevated liver enzymes, impaired glucose 
tolerance, and severity of steatosis on ultrasound). 
Exclusion criteria were any history of cardiovascu-
lar disease, T2DM, renal disease, cholecystectomy, 
or compromised immunity; use of proton-pump 
inhibitors, antibiotics, or anticoagulants in the past 
3  months; any current use of medication; a history 
of moderate to heavy alcohol use (>12 g per day); or 
other causes of liver disease besides NAFLD (e.g., 
hemochromatosis, auto-immune hepatitis, cirrhosis, 
hepatitis B or C, hemochromatosis, alpha-1 antitryp-
sin deficiency, alcoholic liver disease). None of the 
participants underwent bariatric surgery. Fecal donors 
were healthy, lean (BMI < 25 kg/m2), treatment-naïve, 
male or female Caucasian individuals on a stable 
(>3  months) plant-based low-animal-protein (vegan) 
diet. They completed questionnaires on dietary and 
bowel habits, travel history, and comorbidity, includ-
ing family history of diabetes mellitus and medication 
use. Donors were screened for the presence of infec-
tious diseases as recommended.(18,19)
Hepatology CommuniCations, Vol. 4, no. 11, 2020 WITJES, SMITS, ET AL.
1581
stuDy Visits
All participants were advised to retain their usual 
dietary habits during the study and were asked to 
fill out an online nutritional diary for the duration 
of 1  week before the baseline visit and the 24-week 
visit to monitor caloric intake including total calories, 
dietary carbohydrates, fat, proteins, and fibers. Blood 
pressure, body weight, and changes in health status 
were documented.
inteRVention
All visits took place after an overnight fast, with 
plasma samples taken and partly stored at −80°C for 
later analyses. Participants were randomized to treat-
ments with either lean donor or autologous FMT 
performed according to the previously described 
procedure(19) at 8-week intervals (baseline gastro-
duodenoscopy, although at 8  weeks and 16  weeks a 
duodenal tube was placed by means of CORTRAK 
enteral access [Medline Industries, Northfield, IL). 
We have previously observed that gut microbi-
ota composition in the recipient is affected up to 
8-12 weeks after donor FMT,(18,19) so we chose this 
time window to ensure a stable donor gut microbi-
ota composition over this 24-week period. The fecal 
samples received from the donors were collected 
approximately 6 hours before infusion into the recip-
ients. Donors were not specifically matched with 
recipients based on histological or clinical character-
istics. We preferred the use of duodenal infusion for 
FMT administration over infusion through colonos-
copy because of the potential role of the duodenum 
in metabolism, combined with our established expe-
rience with, and the low complication rate of, this 
method at our institution.(18-20)
RanDomiZation anD BlinDing
Subjects were randomized using computerized 
block randomization, using blocks of 4 individuals. At 
the day of FMT, the independent physician provided 
the trial physician with the fecal material with the 
intended treatment from either the assigned donor or 
individual with NAFLD. The study participants (e.g., 
vegan donors and individuals with NAFLD) and all 
trial physicians (including all authors) were blinded 
for the treatment until completion of the trial.
liVeR Biopsy
Percutaneous liver biopsies were performed in the 
recruiting center on the basis of clinical indications 
according to local standard procedure. All histologic 
specimens were scored by a liver pathologist ( J.V.) 
who was blinded to any other results. The NASH 
Clinical Research Network (NASH-CRN) classifi-
cation(20) was assessed with use of hematoxylin and 
eosin–stained slides for steatosis, inflammation and 
ballooning, and with a sirius red–stained slide for 
evaluation of fibrosis. The NAFLD activity score 
(NAS) is the unweighted sum of steatosis (0-3), lobu-
lar inflammation (0-3), and hepatocellular ballooning 
(0-2). RNA for RNA-sequencing analysis was isolated 
using an RNA isolation protocol optimized for (very 
small) percutaneous liver biopsies directly frozen in 
liquid nitrogen after biopsy and stored at −80°C (see 
Supporting Information). RNA-sequencing raw data 
(raw reads) were processed using Kallisto (v0.43.1)(21) 
to obtain gene counts. The R package tximport(22) was 
used to import gene counts into R (v3.4), in which 
differential gene-expression analysis was performed 
using DESeq2 (v1.16).(23) Differential gene expres-
sion aimed to find genes that showed a statistically 
significant interaction between the change in gene 
expression in time (between baseline and 24  weeks) 
and treatment allocation (autologous FMT vs. allo-
genic vegan donor FMT). P values for the interaction 
effects were adjusted using the Benjamin-Hochberg 
correction. Genes with adjusted P values less than 0.1 
were considered significant (i.e., their expression levels 
changed differently in subjects who received autolo-
gous FMT compared with subjects who received allo-
genic vegan donor FMT).
BioCHemistRy
Glucose and C-reactive protein (CRP; Roche, Basel, 
Switzerland) were determined in fasted plasma sam-
ples. In addition, alkaline phosphatase (ALP), gamma- 
glutamyltransferase (GGT),caspartate aminotransferase 
(AST), ALT, total cholesterol, high-density lipoprotein 
cholesterol (HDL-C), low-density lipoprotein choles-
terol (LDL-C), and triglycerides were determined in 
ethylene diamine tetraacetic acid (EDTA) containing 
fasted plasma samples using commercially available 
assays (Randox, Antrim, United Kingdom; and DiaSys 
Diagnostic Systems, Holzheim, Germany). All lipid 
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analyses were performed using a Selectra autoanalyzer 
(Sopachem, Ochten, the Netherlands). LDL-C was 
calculated using the Friedewald formula.
plasma metaBolites
Fasting plasma metabolites were measured at the 
University of Copenhagen. Plasma samples were cen-
trifuged at 2000g for 15  minutes at 4°C from full 
blood mixed with EDTA, then stored at −80°C. The 
order of the samples was randomized within the ana-
lytical batch. Sample processing was performed at 4°C 
using an ice bath. The plasma samples were thawed 
on ice and subjected to protein precipitation using a 
96-well Sirocco plate (Waters Corp., Milford, MA). 
A total of 180  μL of solvent B (acetonitrile : meth-
anol [50:50, vol/vol]) was added to plasma samples 
(40  μL) and spiked with an internal standard mix-
ture of 7 compounds (10  μL), after which analyses 
were performed as previously described(24) (see also 
Supporting Methods and Supporting Table S1).
FeCal miCRoBiota pRoFiling
Fecal samples of donors and participants were 
taken at 0 and 24 weeks after initiation of study and 
analyzed for microbiota composition using 16S ribo-
somal RNA amplicon sequencing.(25) DNA extraction 
from fecal samples was performed using the repeated 
bead beating protocol as previously described.(26) At 
baseline and 24  weeks, individuals with NAFLD 
underwent gastro-duodenoscopy, and duodenal biop-
sies were immediately collected in sterile tubes, snap- 
frozen in liquid nitrogen, and stored at −80°C. DNA 
was isolated from duodenal biopsies using a slightly 
modified protocol, and 16S sequencing was performed 
for small intestinal microbiota profiling as described 
previously(27) (see also Supporting Methods).
poWeR anD stuDy enDpoints
Based on previous intervention studies in NAFLD, 
such as the study of Belfort et al.,(28) in which treat-
ment with pioglitazone in individuals with NASH 
led to a 54% reduction of steatosis compared with 
placebo, we performed a power analysis to calculate 
the number of participants necessary to detect a 25% 
reduction in our primary outcome parameter, reversal 
of steatosis, and necro-inflammation following donor 
FMT. For a desired alpha of 0.05 and a desired power 
of 0.8, a sample size of 27 per arm was needed. Hence, 
54 individuals were needed in total. A data safety and 
monitoring board (DSMB) was appointed for safety 
monitoring. The primary endpoint parameters of this 
study were histological change in NAFLD parameters 
including steatosis and hepatic necro-inflammatory 
activity (ballooning and lobular inflammation follow-
ing NASH-CRN classification), without worsening of 
fibrosis in lean vegan donor versus autologous FMT 
treatment. To assess these outcome parameters, histo-
pathological evaluation of a percutaneously obtained 
liver biopsy sample was performed at baseline and after 
24 weeks (8 weeks after the third FMT) in combina-
tion with changes in hepatic gene expression (using 
RNA sequencing in the liver biopsy taken at baseline 
and after 24  weeks). Secondary outcome parameters 
consisted of the change in intestinal microbiota com-
position between baseline and after 24  weeks. Other 
secondary outcome parameters included change in 
fasting plasma–targeted metabolites, plasma markers 
of fatty liver disease (ALT/AST), and inflammation 
(monocytes) at these time points.
maCHine leaRning anD 
FolloW-up statistiCal 
analyses
For baseline differences between groups, unpaired 
Student t test or the Mann-Whitney U test were used 
dependent on the distribution of the data. Accordingly, 
data are expressed as mean  ±  the SD or the median 
with interquartile range. The change in hepatic ste-
atosis and hepatic necro-inflammatory activity (lob-
ular inflammation and ballooning) following lean 
vegan donor FMT versus autologous FMT was tested 
using a Mann-Whitney U test. Changes in plasma 
biochemistry–derived outcome parameters between 
both treatment groups were tested using a Student 
t test or Mann-Whitney U test, respectively, for nor-
mal and nonparametrically distributed data. For cor-
relation analyses, Spearman’s rank test was used (as 
all parameters were nonparametric). A P value < 0.05 
was considered statistically significant. An Elastic Net 
machine learning classification algorithm in combina-
tion with a stability selection procedure(29) was used 
to identify biological features that changed differently 
between the two treatment groups as previously pub-
lished(19) (see also Supporting Information).
Hepatology CommuniCations, Vol. 4, no. 11, 2020 WITJES, SMITS, ET AL.
1583
Results
Between 2014 and 2017, 26 treatment-naïve obese 
individuals with metabolic syndrome and hepatic ste-
atosis on ultrasound were included. In total, 4 of the 
included NAFLD individuals were excluded before 
randomization due to the diagnosis of new-onset 
T2DM (n = 3) or lost-to-follow-up (n = 1). After ran-
domization, 1 individual had to be excluded due to the 
diagnosis of new-onset T2DM. Due to slow recruit-
ment, after 21 subjects were enrolled and completed 
the study, the trial was prematurely stopped. Baseline 
characteristics of the participants are given in Table 1. 
Daily dietary intake, divided into four macronutri-
ents and caloric content, did not significantly differ 
between the allogenic and autologous FMT recipients 
and remained stable over the course of the study (data 
not shown). Feces from 4 healthy lean vegan donors 
(2 donated three times and five times, respectively; the 
other 2 donated only once) were used for allogenic gut 
microbiota transfer to individuals with NAFLD. The 
same donor was used for the three consecutive FMTs 
in each participant. There were no (serious) adverse 
events or adverse changes in plasma biochemistry, 
and none of the study subjects used any medication 
(including no antibiotics) during the study.
pRimaRy outComes
liver Histology and gene-expression 
alterations after Fmt
Analyzing paired liver biopsies for histology 
(Supporting Table S3), we found no statistically sig-
nificant change in the overall NAS (Fig. 1A) and 
steatosis grade (Fig. 1D). We did, however, observe a 
trend toward improvement in the necro-inflammation 
score (consisting of both lobular inflammation and 
hepatocellular ballooning) (Fig. 1B) after allogenic 
FMT approached significance. Finally, the fibrosis 
scores (Fig. 1C) did not change over the period of 
24 weeks in both groups.
Similarly, there were significant changes in gene 
expression in liver biopsies in the allogenic FMT 
group, compared with the autologous FMT (Fig. 1E). 
For example, ARHGAP18 expression, a protective gene 
that maintains endothelial cell alignment, increased 
following allogenic FMT (P  =  0.002). Furthermore, 
serine dehydratase (SDS) expression was significantly 
increased following allogenic FMT (P  =  0.049). SDS 
catalyzes the conversion of serine into pyruvate, and 
ammonia and is found to be decreased during liver 
damage.(30) In contrast, hepatic expression of RECQL5 
(P  =  0.014), a gene that is implicated in DNA dou-
ble-strand break repair(31) and therefore linked to the 
DNA damage-response signaling pathway,(32) and 
SF3B3 (splicing factor 3b subunit 3) (P  =  0.004), a 
gene promoting cell proliferation and known to be 
an early-stage driver in the development of liver can-
cer,(33,34) both increased following autologous FMT.
seConDaRy outComes
Biochemistry Results 24 weeks after 
Fmt
Following FMT, the GGT levels in the allogenic 
FMT group decreased (mean delta −6.4 ± 8.3, P = 0.038), 
taBle 1. Baseline CHaRaCteRistiCs oF 21 





Age, years 48.5 ± 10.2 51.2 ± 6.6
Male gender, % 96 86
BMI, kg/m2 31.5 ± 4.8 31.7 ± 3.5
Glucose, mmol/L 5.7 ± 0.5 5.8 ± 0.7
AST, IU/L 29.0 [26.5-33.0] 39.5 [37.0-49.5]
ALT, IU/L 48.1 ± 16.5 70.8 ± 23.4
ALP, IU/L 83.0 [54.0-120.5] 71.0 [58.8-76.8]
GGT, IU/L 41.1 ± 21.4 45.1 ± 19.3
Cholesterol, mmol/L 5.8 ± 1.6 6.0 ± 0.8
HDL-C, mmol/L 1.2 [1.0-1.4] 1.2 [1.0-1.4]
LDL-C, mmol/L 4.0 ± 1.3 4.2 ± 0.7
Triglycerides, mmol/L 1.2 ± 0.6 1.4 ± 0.5
CRP, mg/mL 2.2 [0.8-4.3] 1.5 [0.9-3.2]
Leucocytes, 109/L 6.8 ± 1.8 5.8 ± 1.3
Monocytes, 109/L 0.56 ± 0.18 0.54 ± 0.18
Calories, kcal/day 1811.2 ± 376.3 2,024.7 ± 499.3
Fat, g/day 68.6 ± 19.0 80.1 ± 19.6
Carbohydrates, g/day 191.8 ± 53.9 203.7 ± 64.3
Protein, g/day 82.9 ± 19.0 91.2 ± 27.1
Fiber, g/day 22.5 ± 6.2 18.4 ± 8.2
Steatosis, % 35.0 ± 20.7 34.1 ± 20.4
NAS score 2.45 ± 0.82 3.0 ± 0.94
Necro-inflam. score 0.91 ± 0.30 1.4 ± 0.52
Fibrosis score 0.91 ± 0.70 1.2 ± 0.92
Note: Data are expressed as mean ± SD or median [interquartile 
range], depending on the distribution of the data.
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while remaining unchanged in the autologous treated 
individuals (mean delta 0.7 ± 15.4, P = 0.883) (Table 2). 
Furthermore, ALT levels tended to decrease more in 
the allogenic-treated group (mean delta −14.3  ±  24.6, 
P = 0.099) compared with the autologous treated group 
(mean delta −3.1 ± 20.2, P = 0.639).
Fig. 1. Changes in liver histology and gene expression. Error bars show SEMs. (A) NAS score. (B) Necro-inflammation score. 
(C) Fibrosis score. (D) Steatosis score. (E) Liver gene expression. HIST2H2AA3, Histone H2A type 3-A; RASGRF2, Ras Protein 
Specific Guanine Nucleotide Releasing Factor 2; SDS, Serine Dehydratase; RECQL5, RecQ Like Helicase 5; ARHGAP18, Rho GTPase 
Activating Protein 18; GLB1L, Galactosidase Beta 1 Like protein; HSPA12A, Heat Shock Protein Family A (Hsp70) Member 12A; 
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Fmt alters gut microbial 
Composition
There was no difference in fecal microbiota alpha 
diversity (Shannon index) at baseline between individu-
als with NAFLD and allogenic FMT donors (Shannon 
index: NAFLD 4.7 ± 0.4 vs. donor 4.8 ± 0.1, not sig-
nificant). Redundancy analysis showed a trend toward 
distinction in fecal microbiota composition between 
donors and subjects with NAFLD (Supporting Fig. 
S2), together with a significant difference of fiber intake 
in vegan donors (Supporting Table S4). Among oth-
ers, bacteria related to Prevotella were associated with 
a plant-based diet, whereas several groups belonging 
to the Lachnospiraceae were related to the individuals 
with NAFLD. Following FMT, no significant changes 
in fecal microbiota diversity (Shannon index P = 0.84 
for the allogenic FMT; P  =  0.32 for the autologous 
FMT) were observed between baseline and week 24; 
however, a change in gut microbiota composition, 
although not significant, was found following allogenic 
FMT (Supporting Fig. S2). Compared with autol-
ogous FMT, increases in fecal microbiota abundance 
following allogenic FMT were seen in bacteria related 
to Ruminococcus, Eubacterium hallii, Faecalibacterium, 
and Prevotella copri (Fig. 2A). In contrast, autologous 
taBle 2. metaBoliC anD HistologiC paRameteRs aFteR Fmt tReatment
Autologous FMT, 24 Weeks P Value Allogenic FMT, 24 Weeks P Value
Glucose, mmol/L 5.6 ± 0.8 0.241 5.8 ± 0.6 0.945
AST, IU/L 31.5 [18.8-41.3] 0.553 36.0 [29.0-42] 0.116
ALT, IU/L 46.6 ± 23.3 0.639 56.5 ± 19.2 0.099
ALP, IU/L 86.0 [66.8-112] 0.611 70.0 [57.3-83] 0.358
GGT, IU/L 40.7 ± 28.5 0.883 38.7 ± 21.2 0.038
Cholesterol, mmol/L 5.5 ± 1.5 0.055 5.8 ± 0.8 0.139
HDL-C, mmol/L 1.2 [0.9-1.3] 0.280 1.1 [1.0-1.2] 0.308
LDL-C, mmol/L 3.7 ± 1.2 0.099 4.0 ± 0.8 0.378
Triglycerides, mmol/L 1.2 ± 0.6 0.796 1.4 ± 0.4 0.603
CRP, mg/mL 3.5 [0.6-6.3] 0.721 1.5 [0.7-4.4] 0.678
Leucocytes, 109/L 6.6 ± 1.7 0.643 6.0 ± 1.2 0.643
Monocytes, 109/L 0.53 ± 0.18 0.425 0.59 ± 0.25 0.460
Steatosis, % 30.5 ± 25.5 0.316 36.5 ± 25.3 0.527
NAS score 2.64 ± 1.36 0.553 2.8 ± 1.23 0.343
Necro-inflam. score 1.09 ± 0.54 0.341 1.10 ± 0.57 0.081
Fibrosis score 1.18 ± 0.75 0.391 1.60 ± 0.70 0.104
Note: Data are expressed as mean ± SD or median [interquartile range], depending on the distribution of the data.
Fig. 2. Radar plots of significantly altered biological features following either autologous (red) or allogenic (blue) FMT. (A) Fecal 
microbial strains. (B) Plasma metabolites.
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FMT resulted in minor shifts in microbiota composi-
tion, and was primarily associated with changes in the 
abundance of bacteria related to Lachnospiraceae. There 
was no difference in duodenal microbiota diversity and 
composition before and after 24 weeks in either FMT 
group (data not shown).
Fmt alters plasma metabolite 
Composition
Fasting plasma metabolites of both the autolo-
gous and the allogenic treated group significantly 
changed between baseline and 24 weeks after FMT 
(Fig. 2B). Both plasma levels of the amino acids 
isoleucine (P  =  0.039) and phenylacetylglutamine 
(P = 0.027) increased in plasma following allogenic 
FMT (Supporting Table S2). In contrast, plasma 
phenyllactic acid, which is an adverse microbial 
product of aromatic amino acid metabolism, was 
increased following autologous FMT (P  =  0.008). 
Also, plasma levels of desaminotyrosine, a microbial 
metabolite known to trigger type I interferon sig-
naling (IFN1) were increased following autologous 
FMT (P  =  0.008). Finally, we found correlations 
among liver gene expression, fecal gut microbiota 
composition, and plasma metabolite levels following 
either autologous or allogenic FMT, as given in Fig. 3 
and further described in the Discussion.
Discussion
In this study we show the effect of lean vegan 
donor (allogenic) versus own (autologous) FMT on 
obese treatment-naïve individuals with metabolic 
syndrome and biopsy-proven NAFLD, in whom 
NAFLD is typically observed. Although the present 
study was underpowered, allogenic FMT from vegan 
donors on a plant-based, low-animal-protein diet 
decreased the necro-inflammation score in paired liver 
biopsies. In addition, allogenic FMT showed an effect 
on intestinal microbiota composition, which was asso-
ciated with both beneficial changes in plasma metab-
olites and the expression of liver genes involved in 
inflammation and lipid metabolism after donor FMT. 
Using differences in histology data in both treatment 
groups between baseline and 24  weeks after treat-
ment, we calculated that 21 participants per treatment 
arm would have been needed to detect a significant 
beneficial effect of allogenic FMT in the necro- 
inflammation score, whereas 120 participants per 
group are needed to detect a significant difference 
on overall NAS. Therefore, our study could serve as 
a blueprint for sample sizes and specific FMT donor 
selection of future microbiota-based intervention tri-
als in individuals with liver biopsy-proven NAFLD.
inteRaCtions BetWeen 
CHanges in miCRoBiota 
anD liVeR genes/Histology 
FolloWing Fmt
As donor metabolic characteristics can be trans-
ferred by FMT,(18) in this study we opted for FMT 
donors on a plant-based low-animal-protein diet, 
known to have less NAFLD.(11) In line with a 
recent paper that assessed the effect of donor FMT 
on magnetic resonance spectroscopy–derived proton 
Fig. 3. Correlation plot showing significant correlations 
among liver genes, fecal bacteria, and plasma metabolite levels 
(Spearman’s rho); blue, increased in allogenic FMT/decreased in 
autologous FMT; red, increased in autologous FMT/decreased in 
allogenic FMT. Liver histology scores are included in black font. 
HIST2H2AA3, Histone H2A type 3-A; RASGRF2, Ras Protein 
Specific Guanine Nucleotide Releasing Factor 2; SDS, Serine 
Dehydratase; RECQL5, RecQ Like Helicase 5; ARHGAP18, 
Rho GTPase Activating Protein 18; GLB1L, Galactosidase Beta 
1 Like protein; HSPA12A, Heat Shock Protein Family A (Hsp70) 
Member 12A; SF3B3, Splicing Factor 3b Subunit 3.
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density–fat fraction signal in NAFLD, we did not 
find changes in steatosis grade following allogenic 
FMT, as determined by liver biopsy(35); however, 
we did find that liver necro-inflammation score 
improved, which was aligned by significant changes 
in several hepatic genes (Fig. 1). In this regard, the 
ARHGAP18 gene is a protective gene that maintains 
endothelial cell alignment, and loss of ARHGAP18 
may predispose to atherosclerosis development.(36) 
Liver endothelial cells play a pivotal role in main-
taining liver homeostasis, and endothelial cell dys-
function (i.e., loss of fenestrations) occurs early in 
the pathogenesis of NAFLD, promoting steatosis, 
inflammation, and liver fibrosis.(37) Moreover, a 
mutual relation between gut microbiota composi-
tion and liver endothelial cell fenestration has been 
described,(38) with a positive relation between the 
abundance of Firmicutes and endothelial integrity. 
Following allogenic FMT, ARHGAP18 was posi-
tively correlated with E. hallii, suggesting a protec-
tive role of this bacterial species in maintaining liver 
endothelial cell function. Moreover, ARHGAP18 
was inversely correlated with plasma desaminotyro-
sine levels, a microbial metabolite that is known to 
trigger IFN1.(39) Recently it was shown that a high-
fat diet induces an IFN1 response, which results in 
NAFLD progression through metabolically acti-
vated intrahepatic T-cell pathogenicity.(40)
Finally, we observed that after allogenic FMT, 
hepatic SDS expression was significantly increased and 
showed an inverse relation with necro-inflammation 
and steatosis in liver histology (Fig. 3). In human 
liver biopsies, SDS resides predominantly in the 
perivenous region of the hepatocyte,(41) and expres-
sion decreased during liver damage.(30) SDS catalyzes 
the conversion of serine into pyruvate and ammonia, 
and previous studies have linked these metabolites to 
specific microbiota composition, like P. copri abun-
dance.(42) With regard to the latter, in our study NAS 
scores were inversely related with P. copri, which is in 
line with the data reported by Boursier et al.,(10) but 
conflict with other publications that have linked an 
increased abundance of this species to NAFLD.(43) 
Hepatocyte injury and inflammatory cell infiltration 
in the perivenous (efferent) areas of the liver are a 
hallmark of NASH, and this area is involved in gly-
colysis, lipogenesis, ureagenesis from ammonia, and 
biotransformation of plasma compounds, including 
metabolites.(44) Similarly, plasma phenyllactic acid 
levels, which are a microbial product of aromatic 
amino acid metabolism and already linked to NAFLD 
in humans,(45) were inversely related to hepatic SDS 
expression following allogenic FMT. As phenyllactic 
acid is produced by lactic acid bacteria, the observed 
inverse relation between phenyllactic acid and E. hallii 
is interesting to note, as this bacterial species can use 
lactic acid for butyrate production and has beneficial 
metabolic effects in humans.(46) Taken together, our 
data point toward a beneficial role of vegan-donor 
FMT on prevention of NAFLD by reducing specific 
gut microbiota–derived plasma metabolites that are 
toxic to the liver.
inteRaCtions BetWeen 
CHanges in plasma 
metaBolites anD liVeR genes/
Histology FolloWing Fmt
The linear correlation of the SDS gene with iso-
leucine and phenylacetylglutamine (both increased 
in plasma following allogenic FMT) is of interest, as 
a recent paper using genome-scale models indicated 
that individuals with NAFLD have altered metabo-
lism of these amino acids.(47) Alterations in circulating 
amino acids and branched chain amino acids are often 
explained to be the result of impaired amino acid 
metabolism linked to insulin resistance, especially in 
the muscle.(48) Only recently has it been revealed that 
the gut microbiome is associated with plasma metab-
olite alterations of amino acids and branched chain 
amino acids.(42) Our results strengthen the observa-
tion that the gut microbiome contributes to plasma 
amino acids and branched chain amino acid compo-
sition. The inverse relation between plasma phenylal-
anine with the fibrosis score corroborates with older 
literature that phenylalanine metabolism is decreased 
in individuals with hepatopathy, with plasma phenyl-
alanine values decreasing with relatively early liver 
fibrosis.(49)
However, only recently it was shown that meta-
bolic pathways involved in the biosynthesis of phe-
nylalanine are increased in the gut microbiome of 
individuals with NAFLD.(9) Despite the enhanced 
capacity of the gut microbiome to produce phenyl-
alanine, plasma levels are dependent on the liver to 
catabolize this metabolite. Under normal circum-
stances and homeostasis, phenylalanine is converted 
in the liver to tyrosine, and when the liver is not 
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capable of metabolizing phenylalanine, phenyllac-
tic acid and/or phenylacetylglutamine is produced, 
products that are negatively (phenylacetylgluta-
mine)(9) or positively (phenyllactic acid)(45) asso-
ciated with NAFLD according to recent findings. 
Although phenylalanine and downstream metabo-
lites are highlighted in this study, it is most likely 
part of a much broader multifactorial process, only 
partly orchestrated by the gut microbiome. Thus, 
further research to prove the causality of the gut 
microbiome in the development of NAFLD and 
NASH is warranted.
stuDy limitations
First, due to slow recruitment, our study was 
underpowered, as we prematurely had to terminate 
our trial. Second, although we observed no signifi-
cant differences in baseline liver histology (NAFL-
NASH classifications) between the autologous and 
allogenic FMT groups (Table 2), differences in base-
line AST and ALT levels were observed. As partic-
ipants were randomized, this difference occurred by 
chance, but could have influenced the outcome of our 
study. However, if this would be the case, this base-
line difference would have led to an underestimation 
of the allogenic donor effect, as all parameters were 
increased in that group. A third limitation is the use 
of untargeted analysis of hepatic gene expression, as 
the genes found to be differentially expressed are not 
classical markers of hepatic inflammation in NAFLD. 
Another limitation is our choice of FMT donors, as 
donor metabolic characteristics can be transferred by 
FMT.(18) We therefore chose FMT donors consuming 
a plant-based low-animal-protein diet who are known 
to have less NAFLD.(11) However, we did not com-
pare the effect of lean FMT from donors on either 
an omnivorous or plant-based diet. Finally, our pop-
ulation was relatively healthy and did not fully reflect 
the typical individual with NAFLD, who is often 
affected by multiple diseases in addition to NAFLD 
and therefore treated with multiple medications. This 
is reflected by the relatively low necro-inflammation 
score found. However, numerous medications, not 
limited to proton pump inhibitors and antibiotics, 
dramatically alter the gut microbial composition, 
even with interindividual differences.(50) To demon-
strate causality between the gut microbiome and the 
development of NAFLD, the use of medication was 
an exclusion criterion for participation in this study. 
Keeping these limitations in mind, the question to 
what extent the gut microbiome plays a significant 
role in the development of NAFLD and especially in 
individuals with a more progressive form (i.e., higher 
necro-inflammation score) remains to be answered.
In conclusion, our study shows that repetitive allo-
genic donor FMT in individuals with NAFLD affects 
hepatic gene expression and plasma metabolites 
involved in inflammation and lipid metabolism, high-
lighting the crosstalk between gut microbiota com-
position and NAFLD. Therefore, our work not only 
validates previous associative studies on the relation 
between NAFLD and gut microbiota, but also pro-
vides future sample sizes for microbiota-based inter-
vention trials aimed at treating NAFLD in humans.
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